drugset / Trial / NCT04373265
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
NaSingle-groupOpen-labelTreatment
Summary
This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
Timeline
- Start
- 2020-09-30
- Primary completion
- 2023-10-17
- Completion
- 2024-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | — |
| Subject | Relacorilant | Small molecule | 100 mg | Oral |